Trial: 202011122

A Phase 2 Trial Evaluating the Efficacy of Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT)

Phase

II

Principal Investigator

Christopher, Matthew

Disease Site

Acute Myeloid Leukemia (AML); Myeloid and Monocytic Leukemia

Learn more about this study at: clinicaltrials.gov